Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Subjects are randomised to receive posterior fusion using either the CORUS-LX system or the standard posterior fusion method.

Research published in The Lancet Gastroenterology & Hepatology provides robust evidence for the use of a digital visualisation and decision support ...

Successful AI vendors don't rush LLM functionality across all their products without a clear view of the problem they're ...

A little green might not be a cure for the blues. New research suggests medical marijuana isn’t the mental health miracle ...

This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from ...

Retatrutide demonstrated promising results in its first late-stage trial for Type 2 Diabetes, reducing HbA1c levels by up to ...

Isometric exercises – which involve holding certain poses – can build strength and reduce our blood pressure. All you need to ...

Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures post ...

ChemR23 agonism targets inflammatory and neurosensory biology, with receptor expression on ocular immune cells and dorsal root ganglion neurons/glia supporting a mechanistic rationale for NCP symptom ...

Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...